Team 11 : reMoVE-B (CRCI2NA)
CRCI2NA is a French public cancer and immunology research center operating across five sites with 12 teams and over 330 members. Team 11 (reMoVE-B) studies molecular vulnerabilities of tumor escape in mature B-cell malignancies within a multi-disciplinary tumor ecosystem research framework.
- Company typePrivate
- Founded2022
- HeadquartersNantes, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Team 11 : reMoVE-B (CRCI2NA) does
CRCI2NA (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers) is a French public cancer and immunology research center formally created in January 2022 by INSERM (UMR1307), CNRS (UMR6075), Nantes Université, and Université d'Angers. It consolidates oncology and immuno-cancerology research that had been structuring since 1979 and is the largest cancer research center in the Grand Ouest region of France, operating across five sites. The center comprises 12 research teams focused on analyzing tumors as ecosystems, combining cancer genomics, computational biology, cell and molecular biology, 3D and murine cell models, immuno-oncology, and imaging. Cumulative outputs include more than 800 peer-reviewed scientific publications, more than 55 active research projects, and more than 330 members, including 120 PhDs defended since 2015 and 75 HDR-qualified supervisors.
Team 11 (reMoVE-B), the unit under analysis, is one of the 12 teams and focuses specifically on the molecular vulnerabilities of tumor escape in mature B-cell malignancies, examining how malignant B-cells evade treatment within the broader tumor ecosystem framework. CRCI2NA operates a non-commercial revenue model: funding flows from institutional grants provided by its four founding public partners and from competitive national and European research awards. Outputs are disseminated through the HAL open-access publication repository, weekly scientific seminars, graduate training programs (OHNU and I3), the LabEx IGO network, and an Erasmus Mundus Joint Doctorate Program. The customer base is the academic and clinical cancer research community rather than commercial buyers, and there is no commercial pricing, licensing, or product distribution. Governance is led by Director Catherine Pellat-Deceunynck and Deputy Director Philippe Juin.
Team 11 : reMoVE-B (CRCI2NA) firmographics
Firmographics- Name
- Team 11 : reMoVE-B (CRCI2NA)
- Legal name
- CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
- Website
- https://crci2na.univ-nantes.fr
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CRCI2NA is a French public cancer and immunology research center operating across five sites with 12 teams and over 330 members. Team 11 (reMoVE-B) studies molecular vulnerabilities of tumor escape in mature B-cell malignancies within a multi-disciplinary tumor ecosystem research framework.
- Ownership category
- akta.pro rank
Team 11 : reMoVE-B (CRCI2NA) industry classification
Industry- Product category
- Cancer and Immunology Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Team 11 : reMoVE-B (CRCI2NA) is headquartered
LocationHeadquarters
- HQ city
- Nantes
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Team 11 : reMoVE-B (CRCI2NA) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Research Funding: As a public research institution, CRCI2NA generates revenue through government research grants, institutional funding from INSERM, CNRS, Nantes Université, and Université d'Angers, and competitive research project funding.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Team 11 : reMoVE-B (CRCI2NA) product offering
Product offeringCore offering
Team 11 (reMoVE-B) conducts academic research on molecular vulnerabilities of tumor escape in mature B-cell malignancies, operating as one of 12 research teams within CRCI2NA. Its core activity is non-commercial fundamental and translational cancer research, delivered alongside complementary outputs such as graduate training programs (OHNU, I3) and open-access scientific publications distributed via the HAL repository.
Product overview
CRCI2NA is a multi-team cancer and immunology research institution (not a commercial product company) comprising 12 research teams. Team 11 (reMoVE-B) focuses on molecular vulnerabilities of tumor escape in mature B-cell malignancies. The center offers research services, technical platforms, and graduate training programs (OHNU and I3), and produces scientific publications accessible via HAL repository.
Differentiator
Problem solved
Functional benefit
Products and services
- Molecular Vulnerabilities of Tumor Escape in mature B-cell Malignancies (reMoVE-B) Research Academic research program within CRCI2NA dedicated to investigating molecular vulnerabilities that allow tumors to escape therapy in mature B-cell malignancies, for the oncology and immuno-oncology research community.
- Graduate Program OHNU (Oncology, Hematology and Nuclear Medicine) Master's and doctoral training program aimed at training students in oncology and hematology in basic research, applied research in diagnosis, therapeutics, and clinical research, delivered by Nantes Université with CRCI2NA involvement.
- Graduate Program I3 (Immunology & Immunointervention) Master's and doctoral program for students from various backgrounds covering Basic Sciences and Health, focusing on translational research and immuno-intervention applications, delivered by Nantes Université with CRCI2NA involvement.
- Scientific Publications (HAL Repository) Open-access repository providing access to more than 800 scientific publications from CRCI2NA, covering cancer research, immunology, and related fields for the global research community.
Quantifiable outcome
- 800+ scientific papers published
- +2 more outcomes
Companies that use Team 11 : reMoVE-B (CRCI2NA)
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Team 11 : reMoVE-B (CRCI2NA) technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Team 11 : reMoVE-B (CRCI2NA) partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- INSERM (Institut national de la santé et de la recherche médicale)corePrimary institutional partner and co-founder of CRCI2NA. INSERM UMR1307 provides foundational research infrastructure and personnel. One of France's principal public research organizations focused on human health.
- CNRS (Centre national de la recherche scientifique)coreCo-founder partner through CNRS UMR6075. France's largest fundamental research organization providing scientific resources and research framework for the cancer center.
- Nantes UniversitécoreHost university and founding partner of CRCI2NA. Provides institutional framework, facilities, and academic programs including the Graduate School Health Science and Technologies.
- Université d'AngerscoreSecondary academic partner providing research collaboration and contributing to the multi-site structure of the cancer research center across Grand Ouest region.
- LabEx IGO (Laboratoire d'Excellence in Immunology and Oncology)majorCollaborative laboratory of excellence supporting the training axis and research programs. Multiple CRCI2NA members are in charge of training within this initiative.
- Erasmus Mundus Joint Doctorate ProgrammajorInternational doctoral program coordinated by CRCI2NA members, supporting transnational education in oncology and immunology research fields.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Team 11 : reMoVE-B (CRCI2NA) competitors and assessment
Company assessmentDirect peers
- Institut Curie: Premier French public cancer research institution combining a research center and hospital. Operates with a multi-team structure across basic, translational, and clinical oncology research — directly comparable to CRCI2NA's structure and oncology research mission.
- Netherlands Cancer Institute (NKI): Dutch public cancer research institute combining fundamental and clinical research. Comparable as a European academic cancer research center with structured research divisions and a translational focus on tumor biology and treatment resistance — directly overlapping with Team 11's B-cell malignancy research themes.
- German Cancer Research Center (DKFZ): Germany's largest national cancer research center, organized into multiple research programs and divisions. Comparable as a publicly-funded European cancer research institution with multi-disciplinary teams, graduate training, and broad oncology research focus including tumor microenvironment and immuno-oncology.
- Gustave Roussy Cancer Campus: France's largest comprehensive cancer center, combining research, treatment, and education in oncology. Comparable to CRCI2NA as a French public cancer research institution with multiple research teams, graduate programs, and a translational oncology mission — though at substantially greater scale.
- Karolinska Institutet - Department of Oncology-Pathology: Swedish medical university with one of Europe's largest oncology research programs. Comparable as an academic oncology research environment with multi-team structure, graduate training programs, and active research on hematological malignancies and tumor microenvironment.
Others
- INSERM: French national institute for health and medical research, one of CRCI2NA's four founding institutions. While not a direct peer (it is a parent/government funding organization), it operates its own UMR units performing fundamental biomedical research including oncology — providing relevant context for Team 11's institutional ecosystem.
- European Organisation for Research and Treatment of Cancer (EORTC): European intergovernmental cancer research organization coordinating clinical trials and translational research across member institutions. Comparable as a Europe-wide cancer research ecosystem that Team 11/CRCI2NA could collaborate with, though EORTC is a coordinating body rather than a competing research group.
- CNRS: France's largest fundamental research organization and another co-founder of CRCI2NA. CNRS hosts its own cancer and immunology research units, making it an adjacent enabling institution rather than a direct peer — relevant as Team 11's institutional parent and for understanding its funding/governance context.
Broad incumbents
- MD Anderson Cancer Center: Largest US-based cancer center with comprehensive oncology research programs including hematological malignancy research. Comparable in oncology research mission but operates at substantially greater scale, broader therapeutic area coverage, and with industry partnership infrastructure Team 11 lacks.
- Dana-Farber Cancer Institute: Major US-based cancer research and treatment center affiliated with Harvard. Comparable as a multi-disciplinary oncology research institution with deep expertise in hematological malignancies (including B-cell lymphomas) — a larger established global incumbent in the same broad oncology research space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Team 11 : reMoVE-B (CRCI2NA) social profiles
Digital presenceTeam 11 : reMoVE-B (CRCI2NA) compliance and trust
Trust signalCompliance2 records
Team 11 : reMoVE-B (CRCI2NA) financial estimates
Financial estimateRevenue estimate
Valuation estimate
Team 11 : reMoVE-B (CRCI2NA) leadership team
Management profileNumber of profiles
Profiles2 records
Team 11 : reMoVE-B (CRCI2NA) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Team 11 : reMoVE-B (CRCI2NA) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Team 11 : reMoVE-B (CRCI2NA)
What does Team 11 : reMoVE-B (CRCI2NA) do?
Team 11 (reMoVE-B) conducts academic research on molecular vulnerabilities of tumor escape in mature B-cell malignancies, operating as one of 12 research teams within CRCI2NA. Its core activity is non-commercial fundamental and translational cancer research, delivered alongside complementary outputs such as graduate training programs (OHNU, I3) and open-access scientific publications distributed via the HAL repository.
Is Team 11 : reMoVE-B (CRCI2NA) a public or private company?
Team 11 : reMoVE-B (CRCI2NA) is a private company. It is classified as state government owned and is currently operating.
When was Team 11 : reMoVE-B (CRCI2NA) founded?
Team 11 : reMoVE-B (CRCI2NA) was founded in 2022. It employs 1 to 10 people.
Where is Team 11 : reMoVE-B (CRCI2NA) based?
Team 11 : reMoVE-B (CRCI2NA) is headquartered in Nantes, France, in the Europe region.
How does Team 11 : reMoVE-B (CRCI2NA) make money?
One revenue line is on record: research Funding.
Who are Team 11 : reMoVE-B (CRCI2NA)'s main competitors?
Direct peers on record are Institut Curie, Netherlands Cancer Institute (NKI), German Cancer Research Center (DKFZ), Gustave Roussy Cancer Campus and Karolinska Institutet - Department of Oncology-Pathology. Others are INSERM, European Organisation for Research and Treatment of Cancer (EORTC) and CNRS. Broad incumbents are MD Anderson Cancer Center and Dana-Farber Cancer Institute.
Does Team 11 : reMoVE-B (CRCI2NA) have an API?
No public API is recorded for Team 11 : reMoVE-B (CRCI2NA).
What industry is Team 11 : reMoVE-B (CRCI2NA) in?
Team 11 : reMoVE-B (CRCI2NA)'s product category is Cancer and Immunology Research. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.